SE457693B - Komposition med reglerad frigoering vari ett biologiskt material aer loest eller dispergerat i en l2-fas - Google Patents

Komposition med reglerad frigoering vari ett biologiskt material aer loest eller dispergerat i en l2-fas

Info

Publication number: SE457693B
Authority: SE; Sweden
Prior art keywords: phase; monoglyceride; composition according; triglyceride; active material
Prior art date: 1986-07-01

Application number

SE8602931A

Other languages

English (en)

Swedish (sv)

Other versions

SE8602931L (sv

SE8602931D0 (sv

Inventor

S Engstroem

K Larsson

B Lindman

Original Assignee

Drilletten Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1986-07-01

Filing date

1986-07-01

Publication date

1989-01-23

1986-07-01 Application filed by Drilletten Ab filed Critical Drilletten Ab

1986-07-01 Priority to SE8602931A priority Critical patent/SE457693B/sv

1986-07-01 Publication of SE8602931D0 publication Critical patent/SE8602931D0/xx

1987-05-28 Priority to CA000538239A priority patent/CA1296631C/en

1987-06-12 Priority to PCT/SE1987/000279 priority patent/WO1988000059A1/en

1987-06-12 Priority to AT87904411T priority patent/ATE74277T1/de

1987-06-12 Priority to EP87904411A priority patent/EP0314689B1/en

1987-06-12 Priority to JP62504060A priority patent/JPH0759523B2/ja

1987-06-12 Priority to DE87904411T priority patent/DE3778024D1/de

1988-01-02 Publication of SE8602931L publication Critical patent/SE8602931L/

1988-02-09 Priority to NO880560A priority patent/NO175454C/no

1988-02-29 Priority to DK105888A priority patent/DK105888D0/da

1988-12-30 Priority to FI886055A priority patent/FI97687C/fi

1989-01-23 Publication of SE457693B publication Critical patent/SE457693B/sv

1993-08-18 Priority to US08/107,908 priority patent/US5371109A/en

Links

239000000203 mixture Substances 0.000 title claims description 38
230000001105 regulatory effect Effects 0.000 title description 2
239000012620 biological material Substances 0.000 title 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 30
LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 claims description 24
239000011149 active material Substances 0.000 claims description 21
239000007788 liquid Substances 0.000 claims description 21
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 18
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 18
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 15
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 15
102000004169 proteins and genes Human genes 0.000 claims description 14
108090000623 proteins and genes Proteins 0.000 claims description 14
239000000126 substance Substances 0.000 claims description 12
235000013311 vegetables Nutrition 0.000 claims description 12
239000010775 animal oil Substances 0.000 claims description 11
235000021122 unsaturated fatty acids Nutrition 0.000 claims description 11
150000004670 unsaturated fatty acids Chemical class 0.000 claims description 11
239000008158 vegetable oil Substances 0.000 claims description 11
125000004432 carbon atom Chemical group C* 0.000 claims description 10
150000001875 compounds Chemical class 0.000 claims description 10
238000000034 method Methods 0.000 claims description 9
238000013270 controlled release Methods 0.000 claims description 8
239000003921 oil Substances 0.000 claims description 7
238000002360 preparation method Methods 0.000 claims description 5
244000046052 Phaseolus vulgaris Species 0.000 claims description 4
235000010627 Phaseolus vulgaris Nutrition 0.000 claims description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 4
RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 claims description 3
239000003242 anti bacterial agent Substances 0.000 claims description 3
230000015572 biosynthetic process Effects 0.000 claims description 3
RZRNAYUHWVFMIP-HXUWFJFHSA-N glycerol monolinoleate Natural products CCCCCCCCC=CCCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-HXUWFJFHSA-N 0.000 claims description 3
229940074096 monoolein Drugs 0.000 claims description 3
150000003431 steroids Chemical class 0.000 claims description 3
150000003626 triacylglycerols Chemical class 0.000 claims description 3
229930003231 vitamin Natural products 0.000 claims description 3
239000011782 vitamin Substances 0.000 claims description 3
229940088594 vitamin Drugs 0.000 claims description 3
235000013343 vitamin Nutrition 0.000 claims description 3
USPSDZQQNLMVMK-UHFFFAOYSA-N 1-Monolinolein Natural products CCCCCC=CC=CCCCCCCCC(=O)OCC(O)CO USPSDZQQNLMVMK-UHFFFAOYSA-N 0.000 claims description 2
WECGLUPZRHILCT-GSNKCQISSA-N 1-linoleoyl-sn-glycerol Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OC[C@@H](O)CO WECGLUPZRHILCT-GSNKCQISSA-N 0.000 claims description 2
229940088710 antibiotic agent Drugs 0.000 claims description 2
239000003337 fertilizer Substances 0.000 claims description 2
102000039446 nucleic acids Human genes 0.000 claims description 2
108020004707 nucleic acids Proteins 0.000 claims description 2
150000007523 nucleic acids Chemical class 0.000 claims description 2
239000000575 pesticide Substances 0.000 claims description 2
239000008194 pharmaceutical composition Substances 0.000 claims description 2
239000003016 pheromone Substances 0.000 claims description 2
239000011780 sodium chloride Substances 0.000 claims description 2
239000003937 drug carrier Substances 0.000 claims 1
239000012071 phase Substances 0.000 description 53
239000000243 solution Substances 0.000 description 7
JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 6
235000019198 oils Nutrition 0.000 description 6
239000013543 active substance Substances 0.000 description 3
OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 3
238000005538 encapsulation Methods 0.000 description 3
229960000890 hydrocortisone Drugs 0.000 description 3
230000002209 hydrophobic effect Effects 0.000 description 3
238000010587 phase diagram Methods 0.000 description 3
239000012460 protein solution Substances 0.000 description 3
239000003549 soybean oil Substances 0.000 description 3
235000012424 soybean oil Nutrition 0.000 description 3
229930182555 Penicillin Natural products 0.000 description 2
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
235000019486 Sunflower oil Nutrition 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
230000000975 bioactive effect Effects 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
238000006731 degradation reaction Methods 0.000 description 2
239000012530 fluid Substances 0.000 description 2
239000001257 hydrogen Substances 0.000 description 2
229910052739 hydrogen Inorganic materials 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
239000000463 material Substances 0.000 description 2
229930014626 natural product Natural products 0.000 description 2
229940049954 penicillin Drugs 0.000 description 2
239000002600 sunflower oil Substances 0.000 description 2
PROQIPRRNZUXQM-UHFFFAOYSA-N (16alpha,17betaOH)-Estra-1,3,5(10)-triene-3,16,17-triol Natural products OC1=CC=C2C3CCC(C)(C(C(O)C4)O)C4C3CCC2=C1 PROQIPRRNZUXQM-UHFFFAOYSA-N 0.000 description 1
239000004215 Carbon black (E152) Substances 0.000 description 1
102000018832 Cytochromes Human genes 0.000 description 1
108010052832 Cytochromes Proteins 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
102000016943 Muramidase Human genes 0.000 description 1
108010014251 Muramidase Proteins 0.000 description 1
108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000000845 anti-microbial effect Effects 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
238000002144 chemical decomposition reaction Methods 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
239000000084 colloidal system Substances 0.000 description 1
238000010586 diagram Methods 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
230000029087 digestion Effects 0.000 description 1
239000003814 drug Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000008157 edible vegetable oil Substances 0.000 description 1
PROQIPRRNZUXQM-ZXXIGWHRSA-N estriol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1 PROQIPRRNZUXQM-ZXXIGWHRSA-N 0.000 description 1
229960001348 estriol Drugs 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
210000000744 eyelid Anatomy 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
150000002430 hydrocarbons Chemical class 0.000 description 1
150000002431 hydrogen Chemical class 0.000 description 1
125000001165 hydrophobic group Chemical group 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
239000004973 liquid crystal related substance Substances 0.000 description 1
239000007791 liquid phase Substances 0.000 description 1
239000004325 lysozyme Substances 0.000 description 1
229960000274 lysozyme Drugs 0.000 description 1
235000010335 lysozyme Nutrition 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
229940094443 oxytocics prostaglandins Drugs 0.000 description 1
238000005191 phase separation Methods 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
150000003180 prostaglandins Chemical class 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
230000008961 swelling Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases or cochleates; Sponge phases

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Dispersion Chemistry (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Preparation (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

SE8602931A 1986-07-01 1986-07-01 Komposition med reglerad frigoering vari ett biologiskt material aer loest eller dispergerat i en l2-fas SE457693B (sv)

Priority Applications (11)

Application Number	Priority Date	Filing Date	Title
SE8602931A SE457693B (sv)	1986-07-01	1986-07-01	Komposition med reglerad frigoering vari ett biologiskt material aer loest eller dispergerat i en l2-fas
CA000538239A CA1296631C (en)	1986-07-01	1987-05-28	Controlled-release composition
DE87904411T DE3778024D1 (pl)	1986-07-01	1987-06-12
EP87904411A EP0314689B1 (en)	1986-07-01	1987-06-12	A controlled-release composition for a biologically active material dissolved or dispersed in an l2-phase
AT87904411T ATE74277T1 (de)	1986-07-01	1987-06-12	Zubereitung eines in einer l2-phase geloesten oder dispergierten biologischen aktiven materials mit geregelter verabreichung.
PCT/SE1987/000279 WO1988000059A1 (en)	1986-07-01	1987-06-12	A controlled-release composition for a biologically active material dissolved or dispersed in an l2-phase
JP62504060A JPH0759523B2 (ja)	1986-07-01	1987-06-12	調節放出組成物
NO880560A NO175454C (no)	1986-07-01	1988-02-09	Fremgangsmåte for fremstilling av et preparat som har form av en L2-fase
DK105888A DK105888D0 (da)	1986-07-01	1988-02-29	Farmaceutisk middel med kontrolleret frigivelse af det biologisk aktive materiale samt fremgangsmaade til fremstilling af et saadant middel
FI886055A FI97687C (fi)	1986-07-01	1988-12-30	Säännöstellysti vapauttava koostumus L2-faasiin liuotettua tai dispergoitua biologisesti aktiivista ainetta varten
US08/107,908 US5371109A (en)	1986-07-01	1993-08-18	Controlled release composition for a biologically active material dissolved or dispersed in an L2-phase

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
SE8602931A SE457693B (sv)	1986-07-01	1986-07-01	Komposition med reglerad frigoering vari ett biologiskt material aer loest eller dispergerat i en l2-fas

Publications (3)

Publication Number	Publication Date
SE8602931D0 SE8602931D0 (sv)	1986-07-01
SE8602931L SE8602931L (sv)	1988-01-02
SE457693B true SE457693B (sv)	1989-01-23

Family

ID=20364989

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SE8602931A SE457693B (sv)	1986-07-01	1986-07-01	Komposition med reglerad frigoering vari ett biologiskt material aer loest eller dispergerat i en l2-fas

Country Status (8)

Country	Link
EP (1)	EP0314689B1 (pl)
JP (1)	JPH0759523B2 (pl)
CA (1)	CA1296631C (pl)
DE (1)	DE3778024D1 (pl)
DK (1)	DK105888D0 (pl)
FI (1)	FI97687C (pl)
SE (1)	SE457693B (pl)
WO (1)	WO1988000059A1 (pl)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR0148748B1 (ko) *	1988-09-16	1998-08-17	장 크라메르, 한스 루돌프 하우스	사이클로스포린을 함유하는 약학조성물
US6007840A (en) *	1988-09-16	1999-12-28	Novartis Ag	Pharmaceutical compositions comprising cyclosporins
US5196201A (en) *	1989-10-20	1993-03-23	Bioapatite Ab	Implant material composition, preparation thereof as well as uses thereof and implant product obtainable therefrom
EP0429419B1 (en) *	1989-10-20	1996-02-14	Bioapatite Ab	Implant material composition, preparation thereof as well as uses thereof and implant product obtainable therefrom
US5688761A (en) *	1991-04-19	1997-11-18	Lds Technologies, Inc.	Convertible microemulsion formulations
WO1992018147A1 (en) *	1991-04-19	1992-10-29	Affinity Biotech, Inc.	Convertible microemulsion formulations
US6262022B1 (en)	1992-06-25	2001-07-17	Novartis Ag	Pharmaceutical compositions containing cyclosporin as the active agent
YU87892A (sh) *	1991-10-01	1995-12-04	Eli Lilly And Company Lilly Corporate Center	Injektibilne formulacije produženog otpuštanja i postupci za njihovo dobijanje i primenu
SG45449A1 (en)	1992-05-13	1998-01-16	Sandoz Ltd	Ophthalmic compositions
DK0589843T3 (da)	1992-09-25	2002-04-02	Novartis Ag	Cyclosporinholdige farmaceutiske præparater
SE518578C2 (sv) *	1994-06-15	2002-10-29	Gs Dev Ab	Lipidbaserad komposition
SE518619C2 (sv) *	1994-12-09	2002-10-29	Gs Dev Ab	Komposition för reglerad frisättning innehållande monokaproin
ES2177652T3 (es)	1994-11-03	2002-12-16	Novartis Ag	Nuevas formas de preparacion de ciclosporina para la aplicacion oral con composicion simple y alta biodisponibilidad, y procedimiento para su obtencion.
SE504582C2 (sv) *	1995-07-06	1997-03-10	Gs Dev Ab	Cyklosporinkomposition baserad på en L2-fas
DE19544507B4 (de)	1995-11-29	2007-11-15	Novartis Ag	Cyclosporin enthaltende Präparate
KR20050084502A (ko)	1997-01-30	2005-08-26	노파르티스 아게	오일을 함유하지 않은 사이클로스포린 ａ 함유 제약 조성물
DK0942780T3 (da) *	1997-09-09	2003-10-27	Lyotropic Therapeutics Inc	Overtrukne partikler, fremgangsmåder til fremstilling deraf og anvendelse deraf
US6761903B2 (en)	1999-06-30	2004-07-13	Lipocine, Inc.	Clear oil-containing pharmaceutical compositions containing a therapeutic agent
US6458383B2 (en)	1999-08-17	2002-10-01	Lipocine, Inc.	Pharmaceutical dosage form for oral administration of hydrophilic drugs, particularly low molecular weight heparin
US7732404B2 (en)	1999-12-30	2010-06-08	Dexcel Ltd	Pro-nanodispersion for the delivery of cyclosporin
US11304960B2 (en)	2009-01-08	2022-04-19	Chandrashekar Giliyar	Steroidal compositions
US20180153904A1 (en)	2010-11-30	2018-06-07	Lipocine Inc.	High-strength testosterone undecanoate compositions
US9034858B2 (en)	2010-11-30	2015-05-19	Lipocine Inc.	High-strength testosterone undecanoate compositions
US9358241B2 (en)	2010-11-30	2016-06-07	Lipocine Inc.	High-strength testosterone undecanoate compositions
US20120148675A1 (en)	2010-12-10	2012-06-14	Basawaraj Chickmath	Testosterone undecanoate compositions
US9498485B2 (en)	2014-08-28	2016-11-22	Lipocine Inc.	Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
US20170246187A1 (en)	2014-08-28	2017-08-31	Lipocine Inc.	(17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
US20160361322A1 (en)	2015-06-15	2016-12-15	Lipocine Inc.	Composition and method for oral delivery of androgen prodrugs
US20180147215A1 (en)	2016-11-28	2018-05-31	Lipocine Inc.	Oral testosterone undecanoate therapy
US12150945B2 (en)	2018-07-20	2024-11-26	Lipocine Inc.	Liver disease
CN114145290A (zh) *	2021-06-02	2022-03-08	贵州省烟草科学研究院	高效长效昆虫性诱芯及其制作方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA1052697A (en) *	1974-03-29	1979-04-17	Upjohn Company (The)	Composition for treating mastitis in animals
JPS6042766B2 (ja) *	1978-12-09	1985-09-25	日本化薬株式会社	基剤
DE3224619A1 (de) *	1981-07-14	1983-05-19	Freund Industrial Co., Ltd., Tokyo	Orale pharmazeutische zusammensetzung

1986
- 1986-07-01 SE SE8602931A patent/SE457693B/sv not_active IP Right Cessation
1987
- 1987-05-28 CA CA000538239A patent/CA1296631C/en not_active Expired - Fee Related
- 1987-06-12 WO PCT/SE1987/000279 patent/WO1988000059A1/en not_active Ceased
- 1987-06-12 JP JP62504060A patent/JPH0759523B2/ja not_active Expired - Fee Related
- 1987-06-12 EP EP87904411A patent/EP0314689B1/en not_active Expired
- 1987-06-12 DE DE87904411T patent/DE3778024D1/de not_active Expired - Lifetime
1988
- 1988-02-29 DK DK105888A patent/DK105888D0/da not_active Application Discontinuation
- 1988-12-30 FI FI886055A patent/FI97687C/fi not_active IP Right Cessation

Also Published As

Publication number	Publication date
SE8602931L (sv)	1988-01-02
EP0314689B1 (en)	1992-04-01
CA1296631C (en)	1992-03-03
JPH01503140A (ja)	1989-10-26
SE8602931D0 (sv)	1986-07-01
FI97687B (fi)	1996-10-31
DK105888A (da)	1988-02-29
JPH0759523B2 (ja)	1995-06-28
EP0314689A1 (en)	1989-05-10
DK105888D0 (da)	1988-02-29
DE3778024D1 (pl)	1992-05-07
FI886055A7 (fi)	1988-12-30
FI97687C (fi)	1997-02-10
WO1988000059A1 (en)	1988-01-14

Legal Events

Date

Code

Title

Description

1995-01-31

NUG

Patent has lapsed

Ref document number: 8602931-1

Effective date: 19940210

Format of ref document f/p: F

Publication	Publication Date	Title
EP0314689B1 (en)	1992-04-01	A controlled-release composition for a biologically active material dissolved or dispersed in an l2-phase
US5371109A (en)	1994-12-06	Controlled release composition for a biologically active material dissolved or dispersed in an L2-phase
DK175157B1 (da)	2004-06-21	Mikrokapsler, præparat omfattende sådanne mikrokapsler, en krystaldispersion og fremgangsmåde til fremstilling af mikrokapslerne, henholdsvis præparaterne og krystaldispersionen samt anvendelse af mikropaksler
US5662957A (en)	1997-09-02	Oil containing lipid vesicles with marine applications
DE69619700T2 (de)	2002-10-24	Cyclosporin enthaltende, biologisch aktive zubereitung
DE69110052T2 (de)	1995-10-05	Zweiphasige freigabezusammensetzungen für lipophile wirkstoffe.
AU633540B2 (en)	1993-02-04	Encapsulation of parasiticides
CN113558223B (zh)	2024-07-26	一种双重乳液的制备方法及其在虾青素载运中的应用
SE518578C2 (sv)	2002-10-29	Lipidbaserad komposition
EP2871953B1 (en)	2018-07-18	Long-acting nanoparticulate arthropod repellent formulations and methods of use thereof
EP0299205B1 (en)	1992-04-15	Sustained release microcapsules and method for the production thereof
AU2648095A (en)	1995-12-18	Method of preparing a predetermined active agent stock solution for liposomal microencapsulation of active agents for agricultural uses
US20220256842A1 (en)	2022-08-18	New formulation based on an oleo gel, in particular for releasing volatile components, and method for the production thereof
US5258184A (en)	1993-11-02	Emulsions
NO175454B (no)	1994-07-11	Fremgangsmåte for fremstilling av et preparat som har form av en L2-fase
CN121714036A (zh)	2026-03-24	一种基于epa鱼油载花色苷自乳化体系及其制备方法
NO176825B (no)	1995-02-27	Fremgangsmåte for fremstilling av mikrokapsler omfattende lipidkrystaller
SU1296077A1 (ru)	1987-03-15	Способ приготовлени корма дл рыб
JPS6336727B2 (pl)	1988-07-21
HK1205876B (en)	2019-09-27	Long-acting nanoparticulate arthropod repellent formulations and methods of use thereof